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MaOBJECTIVES This study sought to evaluate the long-term prognostic capacity of the SYNTAX (Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score II (SS-II) and compare it with other risk
scores among patients undergoing left main percutaneous coronary intervention (LM-PCI).
BACKGROUND Recently, the SS-II was developed in an attempt to individualize and help the decision-making process
between PCI and coronary artery bypass graft (CABG) surgery in the management of complex coronary artery disease
(CAD). However, there is a paucity of data regarding the utility of SS-II in patients undergoing LM-PCI.
METHODS Data from 1,528 consecutive patients from a single center undergoing unprotected LM-PCI were prospec-
tively collected. The SS-II and other scores were then derived using patients’ baseline clinical characteristics. Patients
were stratiﬁed according to tertiles of SS-II for PCI: SS-II #21 (n ¼ 508), SS-II >21 and #28 (n ¼ 480), and >28
(n ¼ 540). Predictive capability for long-term mortality was compared between angiographic scores and scores
combining both angiographic and clinical variables.
RESULTS At a mean follow-up of 4.4 years, mortality in the ﬁrst, second, and third SS-II tertiles was 1.8%, 3.5%, and
9.4%, respectively (p < 0.0001). Multivariate analysis showed SS-II to be a strong independent predictor of mortality
(hazard ratio: 1.76, 95% conﬁdence interval: 1.10 to 2.82; p ¼ 0.02) after LM-PCI. When compared with the angiographic
SS, scores combining both clinical and angiographic variables, such as the SS-II, were superior in terms of long-term
prognostication.
CONCLUSIONS Results of this large series of consecutive patients who underwent unprotected LM-PCI suggested
that the SS-II has better long-term prognostic power in terms of mortality compared with the original purely angio-
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AB BR E V I A T I O N S
AND ACRONYM S
AUC = area under the curve
CABG = coronary artery bypass
graft
CAD = coronary artery disease
CI = conﬁdence interval
HR = hazard ratio
IDI = integrated discrimination
improvement
LM = left main
MI = myocardial infarction
NRI = net reclassiﬁcation index
PCI = percutaneous coronary
intervention
rSS = residual SYNTAX score
SS = SYNTAX score
SS-II = SYNTAX score II
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1129T he SYNTAX (Synergy Between PercutaneousCoronary Intervention With Taxus and Car-diac Surgery) score (SS) has been shown
to be predictive of adverse outcomes among patients
undergoing percutaneous coronary intervention (PCI)
(1–8). Despite its broad recognition as an important
tool in the decision-making process to select the
most appropriate revascularization strategy between
PCI and coronary artery bypass graft (CABG) surgery
(9–11), the SS has not shown predictive capacity
among patients undergoing CABG (12–16). Moreover,
the lack of inclusion of clinical variables in the SS
has been identiﬁed as a major limitation in its capacity
to accurately stratify patients with complex coronary
artery disease (CAD). Several groups have demon-
strated that the addition of clinical variables increased
the stratiﬁcation capability of the SS (17–21). With
these limitations in mind, the SYNTAX score II
(SS-II) was recently developed, incorporating a com-
bination of angiographic and clinical variables that
have been shown to modify the anatomic SS threshold
where the equipoise for long-term mortality is
reached between PCI and CABG (22). The SS-II, by
incorporating both of these important angiographic
(anatomic SS) and clinical variables (age, sex, left
ventricular ejection fraction, creatinine clearance,
chronic obstructive pulmonary disease, and periph-
eral vascular disease), ensures a more accurate and
individualized mortality prediction, resulting in a
more clinically useful tool for bedside decision mak-
ing in the management of complex CAD. Although
the SS-II was internally validated in the SYNTAX
trial (3) and externally validated in the DELTA regis-
try (23), no other large registries have conﬁrmed its
utility, especially among patients undergoing left
main (LM) PCI only. Moreover, retrospective valida-
tion using a registry, where patients have been
treated according to whether they were more clini-
cally suitable for PCI or CABG, is associated with
an important bias. Therefore, we sought to evaluate
and conﬁrm the prognostic capacity of the SS-II
among patients undergoing LM-PCI only and to
compare its predictive capability with other existing
scoring systems.
METHODS
STUDY POPULATION. Data from all consecutive pa-
tients from a single center (Fu Wai Hospital, National
Center for Cardiovascular Diseases, Beijing, China)
undergoing LM-PCI were prospectively collected.
After excluding patients with previous CABG, the
SS (1) and the residual SS (rSS) (24–28) from all coro-
nary angiograms, using standard quantitativecoronary analysis methodology, were
assessed by an independent angiographic
core laboratory blinded to clinical outcomes.
The SS-II (for both PCI and CABG) were
derived by using patients’ baseline clinical
characteristics as previously described (22).
Brieﬂy, the baseline SS was computed, and,
according to the pre-deﬁned algorithm,
points were added taking into account 6 other
clinical variables (age, sex, left ventricular
ejection fraction, creatinine clearance [in
millimeters per min], chronic obstructive
pulmonary disease, and peripheral vascular
disease), leading to the SS-II. Patients were
stratiﬁed and compared according to tertiles
of SS-II for PCI (22).
Additionally, SS-II for PCI and SS-II for
CABG were compared for each patient. If SS-II
for PCI was greater than the SS-II for CABG
(suggesting that CABG would have been a more
favorable strategy of revascularization), the patients
were labeled as SS-II favoring CABG. Conversely, if
the SS-II for PCI was less than the SS-II for CABG, the
patient was deemed to be a better candidate for PCI
and was labeled as SS-II favoring PCI. Outcomes of
both groups (SS-II favoring PCI vs. SS-II favoring
CABG) were compared.
STUDY ENDPOINTS. Our primary objective was to
assess the capacity of the SS-II for PCI to appropriately
stratify the risk of all-cause mortality in patients un-
dergoing LM-PCI. The association between the SS-II
for PCI and the occurrence of adverse ischemic out-
comes, including death, cardiac death, myocardial
infarction (MI), unplanned target vessel revasculari-
zation (TVR) for ischemia, Academic Research Con-
sortium–deﬁned stent thrombosis (29), and major
adverse cardiac and cerebrovascular events were
assessed as well. The latter was deﬁned as the com-
posite of all-cause death, stroke, MI, or unplanned
TVR for ischemia. All endpoints were adjudicated
centrally by 2 independent cardiologists, and dis-
agreement was resolved by consensus.
We also compared the prognostic value of the SS-II
for PCI with the purely angiographic SS (1) and other
scores (18,19,24), using the receiver-operating charac-
teristic curves, net reclassiﬁcation improvement (NRI),
and the integrated discriminatory index (IDI) (30).
STATISTICAL ANALYSIS. Continuous data are pre-
sented as mean  SD and were compared using the
Student t test or the Mann-Whitney rank sum test, as
appropriate. Categorical variableswere comparedwith
the chi-square or Fisher exact test. Clinical outcomes
were determined using Kaplan-Meier methodology
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1130and compared using the log-rank test. To test for
possible associations between the SS-II and the rates
of long-term mortality, stepwise Cox multivariable
regression analysis was used, with variable entry/stay
criteria of 0.1/0.1. In addition to SS-II risk score, vari-
ables historically known to be associated with long-
term mortality were included in the model. The
proportional hazard assumption was veriﬁed for
each endpoint using the Supremum test. Receiver-
operating characteristic curves were used to compare
the prognostic ability of the various risk scores to
predict the rates of ischemic adverse events. Risk
scores considered were the purely angiographic SS,
rSS, the clinical SS, the logistic SS, and SS-II risk scores.
We also calculated the ability of the SS-II to reclassify
the risk of ischemic adverse events at long-term
follow-up beyond the anatomic SS using the NRI asTABLE 1 Baseline Clinical Characteristics According to SS-II for PCI T
Low Tertile
SS-II #21
(n ¼ 508)
I
Age, yrs 50.3  7.3
Female 22/508 (4.3)
Weight, kg 76.6  9.8
Height, cm 170.5  5.8
Smoking history
Current smoker 224/508 (44.1)
Ex-smoker 96/508 (18.9)
None 188/508 (37.0)
Diabetes mellitus 115/508 (22.6)
Hypertension 237/508 (46.7)
Hyperlipidemia 276/508 (54.3)
Family history of CAD 77/508 (15.2)
Previous myocardial infarction 110/508 (21.7)
Previous PCI 115/508 (22.6)
Previous stroke 18/508 (3.5)
Peripheral vascular disease 0/508 (0.0)
COPD 2/508 (0.4)
LVEF, % 63.6  6.3
Creatinine, mmol/l 78.0  13.6
Creatinine clearance, ml/min 110.3  24.3
Clinical presentation
Stable angina 166/508 (32.7)
Acute coronary syndrome 328/508 (64.6)
Silent ischemia 14/508 (2.8)
PCI access
Radial approach 316/508 (62.2)
Femoral approach 192/508 (37.8)
PCI procedure duration, min 51.4  33.4
Follow-up duration, days 1,601.2  675.0
DAPT >1 yr 488/508 (96.1)
Values are n/N (%) or mean  SD.
CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; DAPT
taneous coronary intervention; SYNTAX ¼ Synergy Between Percutaneous Coronary Intewell as the IDI (30). A p value <0.05 was considered
statistically signiﬁcant. Statistical analyses were per-
formed using SAS version 9.2 (SAS Institute, Cary,
North Carolina).
RESULTS
PATIENTS AND BASELINE CHARACTERISTICS.
From January 2004 to December 2010, 1,528 patients
underwent unprotected LM-PCI at Fu Wai Hospital,
National Center for Cardiovascular Diseases, Beijing,
China. Among the entire cohort, mean values for
baseline SS and rSS were 23.9  7.1 and 4.4  5.9,
respectively, and the calculated SS-II for PCI was 25.6
 7.8, and the SS-II for CABG was 26.7  9.6. Of the
1,528 patients, 963 (63%) had SS-II for PCI less than
the SS-II for CABG, and 565 (37%) had a SS-II forertiles
ntermediate Tertile
SS-II >21 and #28
(n ¼ 480)
High Tertile
SS-II >28
(n ¼ 540) p Value
60.3  7.8 68.8  7.3 <0.0001
108/480 (22.5) 194/540 (35.9) <0.0001
72.4  10.0 67.9  9.9 <0.0001
167.5  6.8 164.8  8.0 <0.0001
<0.0001
116/480 (24.2) 93/540 (17.2)
86/480 (17.9) 91/540 (16.9)
278/480 (57.9) 356/540 (65.9)
118/480 (24.6) 136/540 (25.2) 0.60
272/480 (56.7) 315/540 (58.3) 0.0003
236/480 (49.2) 254/540 (47.0) 0.05
51/480 (10.6) 55/540 (10.2) 0.03
115/480 (24.0) 162/540 (30.0) 0.006
106/480 (22.1) 122/540 (22.6) 0.97
33/480 (6.9) 49/540 (9.1) 0.0009
5/480 (1.0) 75/540 (13.9) <0.0001
3/480 (0.6) 7/540 (1.3) 0.23
63.2  7.0 61.7  8.9 <0.0001
77.1  16.5 89.5  22.3 <0.0001
94.1  26.0 68.4  19.1 <0.0001
0.29
133/480 (27.7) 165/540 (30.6)
335/480 (69.8) 35/540 (65.6)
12/480 (2.5) 21/540 (3.9)
0.005
256/480 (53.3) 289/540 (53.5)
224/480 (46.7) 251/540 (46.5)
56.7  39.4 55.8  35.0 0.05
1,589.5  786.8 1,584.7  745.7 0.93
455/480 (94.8) 513/540 (95.0) 0.59
¼ dual-antiplatelet therapy; LVEF ¼ left ventricular ejection fraction; PCI ¼ percu-
rvention With Taxus and Cardiac Surgery; SS-II ¼ SYNTAX score II.
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1131CABG less than the SS-II for PCI. Baseline character-
istics stratiﬁed by tertiles of SS-II for PCI are pre-
sented in Table 1. Patients in the upper tertile were
older, more frequently female, and shorter; moreTABLE 2 Angiographic and Procedural Characteristics According to S
Low Tertile
SS-II #21
(n ¼ 508)
Angiographic ﬁndings
Isolated LM 67/508 (13.2)
LM þ 1 vessel 154/508 (30.3)
LM þ 2 vessels 173/508 (34.1)
LM þ 3 vessels 114/508 (22.4)
LM lesion type
De novo 496/508 (97.6)
Restenosis 12/508 (2.4)
LM lesion length, mm 20.4  14.5
LM lesion location
Ostium 66/508 (13.0)
Shaft 50/508 (9.8)
Distal bifurcation 392/508 (77.2)
LM bifurcation Medina classiﬁcation
0,0,1 1/392 (0.3)
0,1,0 11/392 (2.8)
0,1,1 6/392 (1.5)
1,0,0 25/392 (6.4)
1,0,1 34/392 (8.7)
1,1,0 203/392 (51.8)
1,1,1 112/392 (28.6)
LM bifurcation with ﬁnal kissing 198/392 (50.5)
LM bifurcation with 2-stent technique 128/392 (32.7)
Type of 2-stent technique
Culotte 9/128 (7.0)
Crush 89/128 (69.5)
T-stent 15/128 (11.7)
Kissing stent 15/128 (11.7)
No. of target lesions 1.62  0.77
Stent implantation 504/508 (99.2)
Type of stents in LM
BMSþPTCA 3.0 (15/508)
First DES 65.4 (332/508)
Second DES 31.7 (161/508)
Stent length 25.4  14.9
Stent diameter 3.5  0.5
No. of stents per patient 1.96  1.06
IVUS use 213/508 (41.9)
Complications during procedure 13/508 (2.6)
Procedural success 505/508 (99.4)
Baseline SS 20.72  5.94
Residual SS 2.67  3.78
Modiﬁed ACEF score 0.80  0.15
Clinical SS 16.43  4.95
Logistic Clinical SYNTAX score 5.49  1.32
SS-II: PCI 17.58  2.17
SS-II: CABG 18.85  5.46
Values are n/N (%) or mean  SD.
ACEF ¼ age, creatinine, ejection fraction; BMS ¼ bare-metal stent(s); CABG ¼ corona
LM ¼ left main; PTCA ¼ percutaneous transluminal coronary angioplasty; SS ¼ SYNTAXfrequently had a previous MI or stroke; and were
more often nonsmokers with lower weight, ejection
fraction, and pre-PCI creatinine clearance. Coronary
disease at baseline was signiﬁcantly more extensiveS-II for PCI Tertiles
Intermediate Tertile
SS-II >21 and #28
(n ¼ 480)
High Tertile
SS-II >28
(n ¼ 540) p Value
<0.0001
22/480 (4.6) 21/540 (3.9)
97/480 (20.2) 63/540 (11.7)
172/480 (35.8) 215/540 (39.8)
189/480 (39.4) 241/540 (44.6)
0.44
462/480 (96.3) 524/540 (97.0)
18/480 (3.8) 16/540 (3.0)
21.9  15.4 23.4  15.8 0.006
0.004
51/480 (10.6) 58/540 (10.7)
24/480 (5.0) 26/540 (4.8)
405/480 (84.4) 456/540 (84.4)
0.01
1/405 (0.2) 4/456 (0.9)
9/405 (2.2) 15/456 (3.3)
6/405 (1.5) 8/456 (1.8)
12/405 (3.0) 16/456 (3.5)
32/405 (7.9) 31/456 (6.8)
180/405 (44.4) 194/456 (42.5)
165/405 (40.7) 188/456 (41.2)
203/405 (50.1) 208/456 (45.6) 0.28
137/405 (33.8) 148/456 (32.5) 0.87
0.29
6/137 (4.4) 7/148 (4.7)
96/1377 (0.1) 95/148 (64.2)
14/137 (10.2) 29/148 (19.6)
21/137 (15.3) 17/148 (11.5)
1.75  0.84 1.71  0.78 0.03
474/480 (98.8) 534/540 (98.9) 0.76
4.2 (20/480) 5.4 (29/540) 0.09
63.5 (305/480) 58.3 (315/540)
32.3 (155/480) 36.3 (196/540)
27.5  15.8 29.2  17.3 0.0009
3.4  0.5 3.3  0.5 <0.0001
2.21  1.14 2.31  1.22 <0.0001
176/480 (36.7) 186/540 (34.4) 0.04
23/480 (4.8) 25/540 (4.6) 0.11
471/480 (98.1) 531/540 (98.3) 0.13
24.69  6.81 26.31  7.14 <0.0001
4.64  6.07 5.86  6.82 <0.0001
0.99  0.24 1.80  0.98 <0.0001
24.33  7.99 47.06  28.61 <0.0001
8.30  1.83 11.06  2.40 <0.0001
24.32  2.04 34.27  5.29 <0.0001
25.80  7.50 34.92  7.61 <0.0001
ry artery bypass graft; DES ¼ drug-eluting stent(s); IVUS ¼ intravascular ultrasound;
score; other abbreviations as in Table 1.
TABLE 3 Adverse Ischemic Outcomes at 4.4 Years of Follow-up According to SS-II Tertiles
Low Tertile
SS-II #21
(n ¼ 508)
Intermediate Tertile
SS-II >21 and #28
(n ¼ 480)
High Tertile
SS-II >28
(n ¼ 540)
p Value
(Trend)
p Value*
1 vs. 2
p Value*
2 vs. 3
p Value*
1 vs. 3
All-cause mortality 9 (1.8) 17 (3.5) 51 (9.4) <0.0001 0.08 0.0001 <0.0001
Cardiac mortality 7 (1.4) 11 (2.3) 29 (5.4) 0.0005 0.28 0.01 0.0002
Noncardiac mortality 2 (0.4) 6 (1.3) 22 (4.1) <0.0001 0.17 0.004 <0.0001
Stroke 9 (1.8) 9 (1.9) 15 (2.8) 0.48 0.90 0.34 0.27
MI 19 (3.7) 35 (7.3) 61 (11.3) <0.0001 0.01 0.03 <0.0001
Q-wave 7 (1.4) 12 (2.5) 30 (5.6) 0.0004 0.20 0.01 0.0001
Clinically driven TVR 49 (9.6) 44 (9.2) 51 (9.4) 0.97 0.80 0.88 0.91
All-cause mortality/stroke/MI 32 (6.3) 52 (10.8) 102 (18.9) <0.0001 0.01 0.0003 <0.0001
MACCE 94 (18.5) 109 (22.7) 158 (29.3) 0.0002 0.10 0.01 <0.0001
ARC stent thrombosis
(deﬁnite/probable)
6 (1.2) 6 (1.3) 14 (2.6) 0.15 0.92 0.12 0.09
Values are n (%). Kaplan-Meier rates estimated at a mean follow-up of 4.4 years. *Bonferroni correction was performed. A p value <0.0167 was considered statistically
signiﬁcant.
ARC ¼ Academic Research Consortium; MACCE ¼ major adverse cardiac cerebrovascular events (the composite of all-cause death, stroke, MI, or clinically driven TVR);
MI ¼ myocardial infarction; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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1132and more complex in the upper SS-II tertiles, with
higher rates of 2- or 3-vessel disease, higher baseline
SS, and higher rSS (Table 2).
ADVERSE ISCHEMIC OUTCOMES. At 4.4-year follow-
up, the rates of all-cause death, cardiac death, MI,
and ischemic-driven TVR in the overall cohort were
5%, 3.1%, 7.5%, and 9.4%, respectively. Clinical
outcomes stratiﬁed according to SS-II tertiles are
shown in Table 3 and Figures 1A to 1F. At a mean
follow-up of 4.4 years, rates of death, cardiac death,
MI, and composite ischemic endpoint were signiﬁ-
cantly higher in the upper tertile than in the inter-
mediate or lower tertiles. After multivariate analysis,
SS-II was an independent predictor of long-term
mortality (hazard ratio [HR]: 1.76, 95% conﬁdence
interval [CI]: 1.10 to 2.82; p ¼ 0.02) after LM-PCI
(Table 4). After adjusting for SS-II, other indepen-
dent predictors of long-term mortality among the
entire cohort include baseline left ventricular ejec-
tion fraction (HR: 0.96, 95% CI: 0.93 to 0.99; p ¼
0.003), the presence chronic obstructive pulmonary
disease (HR: 3.28, 95% CI: 1.00 to 10.75; p ¼ 0.05),
and history of (HR: 1.69, 95% CI: 1.03 to 2.78; p ¼
0.03).
The rates of adverse events stratiﬁed by whether
the SS-II for PCI was greater than the SS-II for
CABG for a given patient (suggesting that CABG
would have been a more favorable strategy for
revascularization) are presented in Table 5. Mortal-
ity was numerically higher in the group with an SS-
II for PCI greater than the SS-II for CABG compared
with the group in which the SS-II for PCI was less
than the SS-for CABG (5.8% vs. 4.6%, respectively,
p ¼ 0.28).PREDICTIVE CAPABILITY OF SS-II AND OTHER
SCORING SYSTEMS. Compared with the strictly
anatomic SS, scoring systems combining clinical
variables and anatomic SS (clinical SS, logistic SS,
and SS-II) had better discrimination and similar cali-
bration for the prediction of long-term mortality
(Figure 2, Table 6). Speciﬁcally, the SS-II had better
discrimination (C-statistic: baseline SS ¼ 0.591 vs.
SS-II ¼ 0.694, p < 0.0001) than the anatomic SS
alone, with both models showing relatively good
calibration and no lack of ﬁtting (chi-square baseline
SS ¼ 3.45, p ¼ 0.90 vs. chi-square SS-II ¼ 6.58,
p ¼ 0.58).
The SS-II signiﬁcantly improved mortality pre-
dictability by appropriately reclassifying several
patients (Table 7). In 77 patients who died at follow-
up, SS-II improved classiﬁcation in 28 and worsened
it in 11, with a net gain in reclassiﬁcation of 17 (22%)
compared with the anatomic SS. In the 1,451 pa-
tients who did not die, SS-II improved classiﬁcation
in 438 and worsened it in 390, for net gain in
reclassiﬁcation of 48 (3%). The NRI of the SS-II over
the anatomic SS was 25% (95% CI: 9.8 to 41; p ¼
0.002). The magnitude of change was relatively
important, with an IDI of 1.5% (95% CI: 0.51 to 2.4;
p ¼ 0.003). Improvement in patients’ reclassiﬁcation
compared with the angiographic SS in terms of long-
term mortality was seen across all scoring systems
that combined clinical and angiographic variables
(Online Tables 1 and 2).
DISCUSSION
The present report is the ﬁrst and the largest real-
world study to speciﬁcally evaluate and compare
FIGURE 1 Kaplan-Meier Curves Showing Event Rates Stratiﬁed by the SS-II Through 5 Years
All-cause death (A); cardiac death (B); myocardial infarction (C); ischemic-driven target vessel revascularization (D); composite of death, myocardial infarction,
and stroke (E); and the composite of death, myocardial infarction, ischemic target vessel revascularization, and stroke (F) stratiﬁed by tertiles of SYNTAX (Synergy
Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score II (SS-II). Except for rate of target vessel revascularization, event rates signiﬁcantly
increased within each SS-II tertile.
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TABLE 4 Predictors of Long-Term Mortality After LM PCI
Variable
Adjusted
Hazard Ratio
(95% CI) p Value
Multivariable Cox Regression Analysis
Age (per 10-yr increase) 1.61 (1.18–2.18) 0.002
Male 1.30 (0.70–2.35) 0.42
LVEF (per 10% increase) 0.57 (0.43–0.74) <0.0001
COPD 4.20 (1.31–13.46) 0.02
Creatinine clearance
(per 10-ml increase)
0.99 (0.88–1.11) 0.85
Previous MI 1.65 (1.01–2.71) 0.05
History of stroke 1.60 (0.81–3.13) 0.18
Multivariable Cox Regression Analysis With SS-II
Age (per 10-yr increase) 1.30 (0.92–1.83) 0.14
Male 1.79 (0.92–3.49) 0.08
LVEF (per 10% increase) 0.65 (0.49–0.86) 0.003
COPD 3.28 (1.00–10.75) 0.05
Creatinine clearance
(per 10-ml increase)
1.06 (0.95–1.17) 0.32
Previous MI 1.69 (1.03–2.78) 0.04
History of stroke 1.60 (0.82–3.15) 0.17
SS-II for PCI
(per 10-point increase)
1.76 (1.10–2.82) 0.02
Each model is adjusted for the variables shown in the table.
CI ¼ conﬁdence interval; other abbreviations as in Tables 1 and 3.
TABLE 5
SS-II Favo
All-cause
Cardiac
Noncard
Stroke
MI
Q-wave
Clinically d
All-cause
MACCE
ARC stent
(deﬁ
Values are n
Abbreviat
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1134the long-term prognostic capacity of the SS-II and
other risk scores to the strictly anatomic SS among a
cohort of consecutive patients undergoing LM-PCI.
The main results of the present study are as fol-
lows: 1) within a population of patients undergoing
LM-PCI, the SS-II for PCI was able to risk-stratify
patients and predict long-term adverse ischemic
events, including mortality; and 2) scoring systems
combining anatomic SS and clinical variables, such asAdverse Ischemic Outcomes at 4.4 Years of Follow-Up According to
ring PCI Versus CABG
SS-II
Favoring PCI
(n ¼ 963)
SS-II
Favoring CABG
(n ¼ 565) p Value
mortality 44 (4.6) 33 (5.8) 0.28
mortality 22 (2.3) 25 (4.4) 0.02
iac mortality 22 (2.3) 8 (1.4) 0.23
25 (2.6) 8 (1.4) 0.11
70 (7.3) 45 (8.0) 0.62
25 (2.6) 24 (4.2) 0.08
riven revascularization 139 (14.4) 71 (12.6) 0.30
mortality/stroke/MI 119 (12.4) 67 (11.9) 0.77
239 (24.8) 122 (21.6) 0.15
thrombosis
nite/probable)
15 (1.6) 11 (1.9) 0.57
(%). Kaplan-Meier rates estimated at a mean follow-up of 4.4 years.
ions as in Tables 1, 2, and 3.the SS-II, demonstrated better predictability for long-
term mortality compared with the strictly anatomic
SS among a population with complex CAD undergo-
ing LM-PCI.
Superiority of scoring systems combining both
anatomic and clinical variables compared with the
strictly anatomic SS has been demonstrated by
several groups (31). Girasis et al. (32) were among the
ﬁrst to show that the addition of patient age, creati-
nine, and ejection fraction (a combination known as
ACEF) to the SS to form the clinical SS signiﬁcantly
improved the ability to predict events for patients
undergoing PCI in the SIRTAX trial (SIRolimus-
eluting stent compared with pacliTAXel-eluting stent
for coronary revascularization) (33). Actually, similar
to our ﬁndings, the clinical SS signiﬁcantly improved
all-cause mortality prediction at 5 years compared
with the SS, with a better discrimination power for
all-cause mortality (area under the curve [AUC]: 0.66,
95% CI: 0.59 to 0.73 vs. AUC: 0.58, 95% CI: 0.51 to
0.65; p < 0.001), and cardiac mortality (AUC: 0.72,
95% CI: 0.63 to 0.81 vs. AUC: 0.63, 95% CI: 0.54 to
0.72; p < 0.002), but not for the composite ischemic
endpoint (death due to cardiac causes, MI, and
ischemia-driven target lesion revascularization).
Similar results were demonstrated in the ARTS II
(Arterial Revascularization Therapies Study II), with
the clinical SS signiﬁcantly improving the predict-
ability of both mortality and composite ischemic
endpoints at 5 years (18). Farooq et al. (19) also
demonstrated that combining meaningful clinical
variables, previously selected on the basis of their
logistic regression coefﬁcients, with anatomic SS—the
so-called logistic SS—results in an enhanced and more
individualized patient stratiﬁcation. Finally, several
groups also demonstrated the incremental prognostic
value of the Global Risk Classiﬁcation score, which
combines the EuroSCORE (European System for Car-
diac Operative Risk Evaluation) and SS to improve
risk prediction of adverse cardiovascular events
compared with the SS alone in patients with complex
CAD undergoing LM revascularization (17,20).
Development of the SS-II was initially intended to
improve and individualize patient stratiﬁcation as a
way to help clinicians decide on the most appropriate
revascularization strategy (PCI vs. CABG). One of the
main ﬁndings of the current report is that, among a
cohort of “real-world” patients deemed suitable for
LM-PCI, the SS-II was able to risk-stratify and identify
patients who will eventually experience adverse
events. The mean SS-II for PCI of the entire cohort
was 25.6  7.8, and the calculated SS-II for CABG
among the entire cohort was 26.7  9.6, suggesting
that globally, according to SS-II stratiﬁcation, this
TABLE 6 Discrimination and Calibration of SYNTAX and Derived Scores for
All-Cause Mortality at 4.4-Year Follow-Up
AUC (95% CI) p Value*
Hosmer-Lemeshow
(p Value)
Anatomic SS 0.591 (0.526–0.656) — 3.45 (0.90)
Residual SS 0.552 (0.488–0.617) 0.11 5.02 (0.76)
Clinical SS 0.729 (0.669–0.790) <0.0001 10.76 (0.22)
Logistic clinical SS 0.728 (0.664–0.792) <0.0001 9.47 (0.30)
SS-II for PCI 0.694 (0.634–0.754) <0.0001 6.58 (0.58)
*For comparison between anatomic SYNTAX score and other scores.
AUC ¼ area under the curve; other abbreviations as in Table 1.
FIGURE 2 Receiver-Operating Characteristic Curve Analyses Comparing the SS With
the Residual SS, the Clinical SS, the Logistic SS, and the SS-II for the Predictability
of Long-Term Mortality
The addition of clinical variables to the anatomic SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery) score (SS) resulted in better
discrimination compared with a strictly anatomic SS. The incremental value on mortality
predictability was similar for all different clinical-anatomic scores compared with a strictly
anatomic SS.
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1135cohort was more suitable for PCI than CABG. How-
ever, among those patients, w40% had an SS-II for
PCI higher than for CABG and were deemed to be
better candidates for CABG per the SS-II algorithm.
Mortality (especially cardiac mortality) was indeed
slightly higher among such patients who underwent
LM-PCI despite CABG being identiﬁed as the most
favorable revascularization strategy. This ﬁnding
importantly illustrates the predictive capability of the
SS-II among a cohort of patients undergoing PCI only.
The SS-II was also shown here to improve pre-
dictability accuracy compared with the strictly
anatomic baseline SS for long-term mortality. Indeed,
SS-II reclassiﬁed patients 25% of the time compared
with baseline SS. In fact, all the scoring systems
combining the angiographic SS with clinical variables
(i.e., clinical SS, logistic SS) substantially enhanced
the prognostic ability of the anatomic SS.
Notably, the rSS (24,25) progressively increases
within each tertile of the SS-II. This ﬁnding illus-
trates the already known correlation between base-
line SS and rSS (24), and it conﬁrms the capacity of
the SS-II to identify patients who not only will more
frequently have adverse events (death and MI) but
also suboptimal revascularization.
In the SYNTAX trial, the lack of antiplatelet ther-
apy at discharge, low ejection fraction, the presence
of peripheral vascular disease, more advanced age,
female sex, previous gastrointestinal bleeding, pre-
scription of amiodarone at discharge, and a higher SS
(per 10 points) were all independently associated
with long-term mortality after PCI (34). Those vari-
ables were then integrated in the SS-II (22). However,
the low number of patients undergoing LM-PCI (n ¼
347) and the low number of related deaths at 4 years
(n ¼ 37, 11.4%) limited the identiﬁcation of predictors
of long-term mortality after LM-PCI. On the other
hand, our study, with w5 times more patients un-
dergoing LM-PCI (n ¼ 1,528), and hence a higher
number of deaths (n ¼ 77, 5% long-term mortality),
offers more power to identify meaningful predictors.
Consideration and selection of those factors in a
combined clinical/anatomic score could be of interest
and reﬁne even more the predictability of the SS-II,
speciﬁcally for LM-PCI. Interestingly, similar to the
SYNTAX trial, diabetes status was not identiﬁed as a
predictor of long-term mortality.
STUDY LIMITATIONS. Despite being the ﬁrst and
largest report to validate the SS-II exclusively in a
population of patients undergoing LM-PCI, this
report has some limitations that should be acknowl-
edged. First, it represents a single-center experience,
with 6 highly experienced operators. This limitationis important because it may affect the generalizability
of our ﬁndings. Indeed, neither the SS nor the SS-II
accounts for operator experience, volume, or tech-
nical skill, and operators’ expertise may have favor-
ably inﬂuenced the prognosis of patients included
in our study, especially in upper tertiles. Second,
determination of the SS is associated with inter-
and intraobserver variability (35), and physiological
assessment (fractional ﬂow reserve–guided) may help
in reducing this variability (36). Another limitation is
that the events were self-reported and not adjudi-
cated, which might underestimate or overestimate
the event rates. Third, discrimination issues have
been raised regarding SS-II risk predictability and
may have also affected our results (37). Fourth,
our validation is restricted to patients undergoing
TABLE 7 Reclassiﬁcation of All-Cause Mortality by Combined
Anatomic-Clinical Scores Versus Anatomic SS
NRI or IDI p Value
SS-II vs. anatomic SS
NRI 0.25 0.002
IDI 0.015 0.003
Clinical SS vs. anatomic SS
NRI 0.32 <0.0001
IDI 0.028 0.002
Logistic SS vs. anatomic SS
NRI 0.26 0.001
IDI 0.046 <0.0001
IDI ¼ integrated discriminatory index; NRI ¼ net reclassiﬁcation index; other
abbreviations as in Table 1.
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1136LM-PCI and did not include patients undergoing
CABG. Finally, given the retrospective nature of our
analysis, our ﬁndings should be considered hypoth-
esis generating.CONCLUSIONS
The current report, drawn from a large cohort of
consecutive patients undergoing LM-PCI, conﬁrms
the incremental value of scoring systems combining
both clinical and angiographic variables (such as the
SS-II) in the decision-making process when facing
complex CAD and validates the superiority of the
SS-II compared with the purely angiographic SS to
risk-stratify patients undergoing LM-PCI.
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